Gestión del peso

Mazdutide

CAS #: 2256232-71-4

Mazdutide is a once-weekly injectable dual GLP-1/glucagon receptor agonist, the first in its class. It reduces appetite and improves blood sugar control through GLP-1 while boosting energy expenditure and fat burning through glucagon activation. Approved in China; clinical trials show up to 14% body weight reduction over 48 weeks and 68% liver fat reduction. Available as solution for injection.

Número CAS 2256232-71-4
Fórmula molecular OXM analog
Peso molecular ~4500 g/mol
Secuencia/Composición GLP-1/GCG dual agonist

SKU disponibles

Modelo Especificación MOQ
mazdutide-5 5 ml 1 vial
mazdutide-10 10 ml 1 vial
mazdutide-20 20 ml 1 vial
Envío en 3-5 días laborables
Certificado de análisis incluido
Calidad garantizada

Productos

Mazdutide (IBI362/LY3305677), developed by Eli Lilly and Innovent Biologics, is an analog of oxyntomodulin (OXM) that activates both GLP-1 and glucagon receptors. Approved in China as Xinermei in June 2025, it is the first marketed dual GCG/GLP-1 receptor agonist. Clinical data published in Nature, Lancet, and NEJM support its efficacy. Global Phase III trials are underway.

Mecanismo de acción

Mazdutide mimics two natural gut hormones simultaneously: GLP-1 (reduces appetite, slows digestion, supports blood sugar control) and glucagon (increases energy expenditure, promotes fat burning, stimulates changes in liver, brain, and adipose tissue). The GLP-1 component counteracts glucagon's glucose-raising effect, creating a net benefit in both weight loss and glycemic control.

Principales ventajas

Significant Weight Loss — Clinical trials demonstrate 11–14% body weight reduction over 48 weeks. Dual mechanism produces greater weight loss than GLP-1-only treatments through combined appetite suppression and increased energy expenditure.

Metabolic Health Improvement — Reduces waist circumference, blood sugar levels, cholesterol, and blood pressure beyond weight loss alone.

Salud hepática — 10mg dose reduced liver fat by 68% after 32 weeks in MAFLD patients; 70% achieved normal liver fat levels after 48 weeks.

Convenient Once-Weekly Dosing — Single weekly injection provides sustained dual-receptor activation for consistent metabolic support.

Referencias

  1. Ji L, et al. Safety and efficacy of mazdutide (IBI362) in Chinese adults with overweight or obesity. *EClinicalMedicine.* 2022;54:101691.
  2. Guideline for Chronic Weight Management and Clinical Practice of Anti-obesity Medications (2024). *Chin J Endocrinol Metab.* 2024;40(7):545–564.
  3. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. *N Engl J Med.* 2023.

Asistencia técnica

Nuestro equipo está disponible 24 horas al día, 7 días a la semana, para ayudarle con sus preguntas sobre productos y asistencia técnica.

Contacto

Servicios OEM

¿Necesita modificaciones o mayores cantidades? Póngase en contacto con nosotros para obtener un presupuesto personalizado.

Solicitar a medida
Número CAS 2256232-71-4
Fórmula molecular OXM analog
Peso molecular ~4500 g/mol
Secuencia/Composición GLP-1/GCG dual agonist
Aminoácidos ~30
Formulario Polvo liofilizado
Pureza ≥99% por HPLC
Almacenamiento -20°C desecado

Productos relacionados

¿Necesita una configuración OEM o personalizada?

Ofrecemos síntesis personalizadas, modificaciones y servicios OEM. Comuníquenos sus requisitos (secuencia, pureza, cantidad y necesidades especiales) y nuestro equipo le enviará un presupuesto detallado.

Solicitar síntesis personalizada Contacte con nosotros